Raising the standards of clinical trials and research
The James Lind Library, named after the 18th-century Scottish naval surgeon whose experiments showed that citrus fruits cured scurvy, was launched in 2003 to broaden understanding of clinical trials involving humans by explaining their fundamental principles and their historical development. The online repository receives over 60 000 visitors every three months, and WHO Regional Offices have translated its introductory materials into Arabic, French, Portuguese and Spanish. The library provides access to passages from books, essays, articles and a wealth of other materials dedicated to patient care and transparent trials. Library editor Sir Iain Chalmers describes the challenges confronting improved clinical trials.
Q: Why are clinical trials important, and how does the James Lind Library fit in?
A: The James Lind Library is an educational resource helping people understand why trials are necessary. Public knowledge on how to assess whether claims about the effects of treatments are unacceptably dangerous or beneficial is not very available. What the James Lind Library attempts to do is explain that it is very easy to cause unintended harm with treatments and public health measures. The motivation for doing clinical trials is to try both to reduce the harm and increase the good that we do. But unless those trials are done carefully they may be misleading. It is important not just to acknowledge that conducting trials is important, but also that they should be done well, and analysed responsibly and validly. The James Lind Library's main responsibility is to introduce people to those principles.
Q: Is the scientific, medical, clinical trial community adhering to these principles?
A: There are some areas where there has been improvement, such as in the design of studies and the quality of reports. But other problems have become more prominent, particularly the way in which investigators too frequently don't publish results of their studies when they are disappointed with them. Obviously that introduces a bias into what is available to the public and upon which they base treatments. Let's say you as a patient went to your doctor for treatment and your doctor only had access to studies showing positive effects of the treatment he or she offered to you, when in fact the important information on the negative effects had never been published. As a patient you would be receiving a treatment based on a decision distorted by not having access to all the relevant evidence. The treatment may not be effective and, even worse, it may be harmful.
Q: What can fix the system?
A: Governments can do much more, particularly their licensing authorities. Governments can set up measures through laws or regulations to insist that the whole clinical trial process is more transparent. That entails registering trials before their results are known. Within that registration process, which should be open to public scrutiny, the protocols for research should also be made public. One type of reporting bias is that whole studies don't get published. Another is that the outcomes that were initially envisaged as being important are not those that appear in the final report.
Governments can do various things to encourage transparency in clinical trials so that science and the discovery process can be more efficient. Too much secrecy exists in science, which makes it inefficient. Many analysts have shown that new drug discoveries during the last 20 years have been very disappointing considering the massive investment in research.
But a problem exists for any government when the pharmaceutical industry is a major part of that country's economy. Governments try to keep commercial operations happy; otherwise they face threats from companies to move their operations to other countries. There are forces operating against pushing for proper scientific behaviour. This is not a problem limited to people with vested commercial interests. It also exists throughout academia, where people do not systematically assess what is known already before embarking on new research.
Q: How beneficial is the WHO International Clinical Trials Registry Platform?
A: This is a very important initiative, because there has been so little experience in developing trial registers. We are talking about experience that goes back only a decade and it is a great challenge to make sure it is done well. WHO, as the leading health organization in the world, has a leadership role to set standards. Quite rightly, WHO points out that greater transparency in clinical trials is a moral issue; and that it is a matter of moral concern that the trial process is not more transparent. After all, people are being invited to participate in clinical trials and it should be recognized that there is a duty of care to those people to ensure transparency.
All of WHO's activities depend on country support and it has the challenge of promoting progress at a rate that the major players can accept. It is obviously going to be a matter of judgement how best to do that. For example, a judgement was made recently that registers being developed in China and India should be accepted as primary registers in the WHO platform programme. The arguments in favour are that if you have two large economies like China and India signed up, as well as countries in Australasia, Europe and North America, you are encouraging recognition that this is a global issue that must be addressed at an international level. Others say it was premature to give such prominence to registers (in China and India) that are at very early stages of development.
Q: How do you regard the International Committee of Medical Journal Editors' bid to make trialists and sponsors more accountable by agreeing not to publish results of any trial unless it has been publicly registered before the first patient's enrolment?
A: This was very important, but the trouble is that it came about two decades late. It was precipitated not by the strong scientific and moral reasons for trial registration, but by a law case brought by the attorney general of New York State against a drug company for withholding data that should have been in the public domain. It is a great shame that a law case was needed to make the world's leading medical scientific journals take a stand that they could have made years before.
Surveys have shown repeatedly that a great deal of rubbish is published in medical journals. We need to acknowledge more openly that the much-vaunted ritual of peer review leaves substantial room for improvement. One very senior editor, Richard Smith (a former editor of the BMJ), has actually suggested in a recent article that journals should no longer be allowed to publish clinical trials because there are so many biases in the journal procedure itself. One of the ways in which medical journals make their money is by selling reprints of articles, and they know some studies are more likely than others to generate reprint income from commercial sponsors.
The most important thing is to ask the question: "Is the information that is being made available from clinical trial research the best that could be provided to promote the interests of patients and the public?" That should be the yardstick by which proposals are judged. Too often things get in the way like academic credit, the profitability of journals or drug companies, or undeclared conflicts of interest among investigators. It is important to repeatedly remind oneself that the clinical trials business should be about trying to improve health care and the health of people. But as long as distortions exist in the research design and reporting processes, we won't have done as well as we could for the public interest.
Q: Can we ever expect full compliance and transparency from players involved in trials when so many interests are involved?
A: The Universal Declaration of Human Rights [adopted by the UN General Assembly in 1948] was a declaration of principles to which governments were invited to sign up. It is important that the declaration was issued because it provided benchmarks against which we think the behaviour of human beings to each other should be judged. More than any other actors in this arena, governments are responsible for trying to ensure those principles are observed. The same applies to the problems in current clinical trial enterprises. There are standards that should be set and everyone, particularly governments, should do what they can to ensure compliance.
But there will always be backsliding because the stakes are often very high, particularly the financial stakes for some players in this business. But something else is at stake too, and that is human health. It really does come down to a question on how you balance the interests of human beings who wish to improve and maintain their health, and what we can do about that, against other interests, such as financial, political and academic kudos.